Author Index for Volume 24

A

Aholt D, 404

B

Beauman SS, 367
Brownlee KG, 297
Bryant R, 169

C

Catney MR, 332
Chopra PS, S35
Collins SE, 375
Connelly T, 332
Conway SP, 297
Craven DE, 180

D

Das A, 297
Dobbs Jr LJ, 311
Dobson PM, 385
Domino L, 332
Duffy ME, 25

F

Farr BM, 180
Figueredo A, 38
Fry C, 404

G

Giarelli E, 301

H

Hanchett M, 244
Hanchett M, 56
Harris JS, 180
Heath J, 102
Hillis S, 332
Holland J, 95

J

Jackson D, S28
Jones G, 38
Jones KC, 381
Jones S, 102

K

Kaufman JA, S23
Keller S, 332

L

Langkamp-Henken B, 124
Lynch M, 85

M

Major P, 38
Mayo DJ, S13
Mermel LA, 180
Miall LS, 297
Modak S, 395

O

O'Grady N, 180
Odesina V, 32
Oishi LA, 174

P

Palefski SS, 113
Pirrung MK, 107
Price D, 332

R

Raad II, 180
Rayhorn N, 255
Rebellato LM, 311
Rihn TL, S9
Royer T, 326

S

Saborio DV, 395
Sampath LA, 395
Scholl D, 124
Scroggins NM, 263
Sherertz RJ, 180
Simpson L, 332
Snelling R, 38
Soderburg LM, 159
Sterba KG, 249
Stoddard GJ, 113

W

Wagner K, 332
Wakefield B, 332
White M, 332
White SA, 19
Wilder GL, 319
Wood L, 48

Y

Yaron I, 395

Author Index for Volume 24

A

Aholt D, 404

B

Beauman SS, 367
Brownlee KG, 297
Bryant R, 169

C

Catney MR, 332
Chopra PS, S35
Collins SE, 375
Connelly T, 332
Conway SP, 297
Craven DE, 180

D

Das A, 297
Dobbs Jr LJ, 311
Dobson PM, 385
Domino L, 332
Duffy ME, 25

F

Farr BM, 180
Figueredo A, 38
Fry C, 404

G

Giarelli E, 301

H

Hanchett M, 244
Hanchett M, 56
Harris JS, 180
Heath J, 102
Hillis S, 332
Holland J, 95

J

Jackson D, S28
Jones G, 38
Jones KC, 381
Jones S, 102

K

Kaufman JA, S23
Keller S, 332

L

Langkamp-Henken B, 124
Lynch M, 85

M

Major P, 38
Mayo DJ, S13
Mermel LA, 180
Miall LS, 297
Modak S, 395

O

O'Grady N, 180
Odesina V, 32
Oishi LA, 174

P

Palefski SS, 113
Pirrung MK, 107
Price D, 332

R

Raad II, 180
Rayhorn N, 255
Rebellato LM, 311
Rihn TL, S9
Royer T, 326

S

Saborio DV, 395
Sampath LA, 395
Scholl D, 124
Scroggins NM, 263
Sherertz RJ, 180
Simpson L, 332
Snelling R, 38
Soderburg LM, 159
Sterba KG, 249
Stoddard GJ, 113

W

Wagner K, 332
Wakefield B, 332
White M, 332
White SA, 19
Wilder GL, 319
Wood L, 48

Y

Yaron I, 395

Subject Index for Volume 24

Note: Page numbers preceded by S refer to the May/June Supplement.

A

Adolescents. *See also* Children
  inflammatory bowel disease in, 255
Allergic reaction, to asparaginase, protocol for, 169
Alteplase, 319
  for catheter occlusion, S9, S13
American College of Critical Care Medicine, infection management guidelines of, 180
Amifostine, clinical trials of, 48
Analgesia, 85
Anesthesia, local, for peripherally inserted central venous catheter insertion, 404
Antibiotics
  IV, for sickle cell disease, 32
  novel, 319
Anticytokine therapy, 319
Antifungals, novel, 319
Anti-IgE antibody, 319
Antineoplastic agents. *See* Chemotherapy
Antiseptic catheter, improved chlorhexidine-impregnated, 395
Aperezolid, 319
Arginine, for wound healing, 124
Arteriovenous conduit, for hemodialysis, S35
Ascorbic acid, for wound healing, 124
Asparaginase, hypersensitivity reactions to, protocol for, 169
Asthma, anti-IgE antibody for, 319

B

Basiliximab, 319
Biopharmaceuticals, 319
Blood transfusions, in sickle cell disease, 32
Bone marrow transplantation, haploidentical, 311

C

Cancer
  gastrointestinal, tunneled centrally placed vs. peripherally inserted central venous catheters in, 38
  home infusion services in, quality of life and, 244
  inherited, genetic testing for, ethical issues in, 301
  innovative agents for, clinical trials of, 48
Capecitabine, clinical trials of, 48
Caspofungin, 319
Catheter(s)
  central venous. *See* Central venous catheter(s)
  hemodialysis, S35
  improved chlorhexidine-impregnated antiseptic, 395
  peripheral IV
    dwell time of, phlebitis and, 332
    placement of by infusion vs. generalist nurses, complications after, 113
    routine replacement of, 249
Catheter occlusion
  fibrinolytic therapy for, S9, S13
  prevention of
    elastomeric continuous infusion device for, 102
    saline vs. heparin flush for, 249
Catheter placement
  by infusion vs. generalist nurses, complications after, 113
  local anesthesia for, 404
  microintroducer and venous ultrasound for, 326
Catheter-related complications, after placement by infusion vs. generalist nurses, 113
Catheter-related infections
  in children, 174
  diagnosis of, S28
  epidemiology of, S28
  management guidelines for, 180
  prevention of, S28
  signs and symptoms of, S28
Catheter-related thrombosis, S9, S13
  catheter occlusion by. *See* Catheter occlusion
Central venous catheter(s). *See also* under Catheter
  dressings for, 249
  in long-term/subacute care clients, care and maintenance of, 249
  occlusion of, fibrinolytic therapy for, S9, S13
  peripherally inserted
    in cystic fibrosis, 297
    insertion of
      local anesthesia for, 404
      microintroducer and venous ultrasound in, 326
    vs. tunneled centrally placed, in gastrointestinal cancer, 38
  placement of, image-guided, S23
  saline vs. heparin flush for, 249
Central venous catheterization, database design and creation for, 159
Chemotherapy
  for gastrointestinal cancer, tunneled centrally placed vs. peripherally inserted central venous catheters for, 38
  innovative agents in, clinical trials of, 48
Children. *See also* Adolescents
  catheter-related infections in
    management of, 180
    prevention of, 174

infusion therapy in, competencies in, 367
peripheral IV catheters for, routine replacement of, 174
phlebitis in, 174
Chimerism studies, for hematopoietic stem cell transplant, 311
Chlorhexidine-impregnated antiseptic catheter, improved, 395
Clinical trials, of innovative antineoplastic agents, 48
Code of Ethics (INS), 242
Competencies, pediatric, 367
Continuing education, review questions for, S5
CRNI Certification Examination, review questions for, 17, 83, 157, 240, 295, 357
CRNI/CLNI Recertification Examination, review questions for, S5
Crohn's disease, in adolescents, 255
Cystic fibrosis, peripherally inserted central venous catheters in, 297
Cytoprotective agents, clinical trials of, 48

D

Daclizumab, 319
Dalfopristin, 319
Database, central venous catheter, design and creation of, 159
Dialysis, venous access for, S35
Docetaxel, clinical trials of, 48
Doxorubicin, liposomal, clinical trials of, 48
Dressings, for venous access devices, 249
Drotrecogin alfa, 319
Dwell time, phlebitis and, 332

E

Editorials, 5, 71, 143, 213, 281, 351
Elastomeric continuous infusion device, for maintenance of catheter patency, 102
Elderly
central venous catheter care and maintenance in, 249
maintaining infusion services for, 381
Electronic charting system, design and implementation of, 159
Embolism, pulmonary, catheter-related thrombosis and, S13
Etanercept, 319
Ethical code, of Infusion Nurses Society, 242
Ethical issues, in genetic testing, 301

F

Familial cancer, genetic testing for, ethical issues in, 301
Fibrinolytics
for catheter occlusion, S9, S13
novel, 319
Fibrin sheath obstruction, catheter-related, S13
Fistula, native arteriovenous, for hemodialysis, S35
Fluid management
in sickle cell crisis, 32
for wound healing, 124
5-Fluorouracil, for gastrointestinal cancer, tunneled centrally placed vs. peripherally inserted central venous catheters for, 38

G

Gastrointestinal cancer, tunneled centrally placed vs. peripherally inserted central venous catheters in, 38
Gatifloxacin, 319
Gemtuzumab, 319
Genetic testing, ethical issues in, 301
Grafts, prosthetic, for hemodialysis, S35

H

Haploidentical transplantation, 311
Health outcomes research study, design of, 25
Hematopoietic stem cell transplantation, haploidentical, 311
Hemodialysis, venous access for, S35
Heparin, low molecular weight, 319
Heparin flush, vs. saline flush, 249
HLA typing, for hematopoietic stem cell transplant, 311
Home infusion therapy
for cancer patients, quality of life and, 244
multifactorial model for, 385
Hypersensitivity reactions, to asparaginase, protocol for, 169

I

Image-guided central venous catheter placement, S23
Immunosuppressants, novel, 319
Infection control practices, 180, S28
Infections. *See* Catheter-related infections
Infectious Diseases Society of America, infection management guidelines of, 180
Inflammatory bowel disease, in adolescents, 255
Infliximab, 319
Infusion Nurses Society
Chief Executive Officer's report, 234
Code of Ethics, 242
Presidential Address, 231
State of the Society Address, 227
Infusion nursing. *See also* Intravenous therapy
liability issues in, 375
nursing theory in, 56
outcomes research in, study design for, 25
pediatric competencies in, 375
Infusion Nursing Standards of Practice, compliance with, 249
Infusion therapy, home-based
for cancer patients, quality of life and, 244
multifactorial model for, 385
Inherited cancer, genetic testing for, ethical issues in, 301
Insulin analogs, novel, 319
Interventional radiology, in central venous catheter placement, S23
Interventional technology, nurse-driven, 326
Intravenous Nurses Society. *See* Infusion Nurses Society
Intravenous therapy
phlebitis in
in children, 174
rates of, 19
in sickle cell crisis, 32
theory-practice gap in, 56
Iodine-131 tositumomab, 319

L

Liability risks, 375
Linezolid, 319
Local anesthesia, for peripherally inserted central venous catheter insertion, 404
Long-term/subacute care clients
central venous catheter care and maintenance in, 249
maintaining infusion services for, 381
Low molecular weight heparin, 319

M

Malpractice, 375
Maxifloxacin, 319
Microintroducer and venous ultrasound, in placement of peripherally inserted central venous catheters, 326
Monoclonal antibodies, 319

clinical trials of, 48
Multiple endocrine neoplasia type 2a, genetic testing for, ethical issues in, 301
Myocardial infarction, inferior wall, diagnosis and management of, 263

N

Narcotic analgesics, 85
Native arteriovenous fistula, for hemodialysis, S35
New products and services, 61, 133, 206, 268, 342
Nursing theory, for infusion nursing, 56
Nutrition, in wound healing, 124

O

Omalizumab, 319
Opioid analgesics, 85
Outcomes research study, design of, 25

P

Paclitaxel, clinical trials of, 48
Pain, assessment of, 85
Pain management, 85
in peripherally inserted central venous catheter placement, 404
Pediatric competency program, didactic components of, 367
Peripheral IV catheters. *See also* Catheter(s)
dwell time of, phlebitis and, 332
placement of, by infusion vs. generalist nurses, complications after, 113
routine replacement of, 249
in children, 174
Peripherally inserted central venous catheters. *See also* Central venous catheter(s)
in cystic fibrosis, 297
placement of
local anesthesia for, 404
microintroducer and venous ultrasound in, 326
vs. tunneled centrally placed, in gastrointestinal cancer, 38
Phlebitis
catheter dwell time and, 332
in children, 174
rates of, 19
Prosthetic grafts, for hemodialysis, S35
Protein, for wound healing, 124
PTFE grafts, for hemodialysis, S35
Pulmonary embolism, catheter-related thrombosis and, S13

Q

Quality of life, in cancer patients, home infusion services and, 244
Quinolones, third-generation, 319
Quinupristin, 319

R

Radiation therapy, advances in, 95
Radiology, interventional, in central venous catheter placement, S23
Recombinant plasminogen activator, for catheter occlusion, S9, S13
Regional enteritis, in adolescents, 255
Research study, health outcomes, design of, 25
Reteplase, for catheter occlusion, S9, S13
Right ventricular infarcts, diagnosis and management of, 263
Rituximab, 319
clinical trials of, 48

S

Saline flush, vs. heparin flush, 249
Sickle cell crisis, IV support in, 32
Society for Healthcare Epidemiology of America, infection management guidelines of, 180
Sparfloxacin, 319
Standard Precautions, S28
Standards of Practice, compliance with, 249
Stem cell transplantation, haploidentical, 311
Sterile dressings, for venous access devices, 249
Subclavian vein thrombosis, catheter-related, S13
Superior vena cava thrombosis, catheter-related, S13

T

Taxanes, clinical trials of, 48
Teicoplanin, 319
Tenectelase, 319
Tenzaparin, 319
Thrombolytics
for catheter occlusion, S9, S13
novel, 319
Thrombosis, catheter-related, S9, S13. *See also* Catheter occlusion
Tissue plasminogen activator, for catheter occlusion, S9, S13
Toxic epidermal necrolysis, management of, 107
Transfusions, in sickle cell disease, 32
Transmission Blood Precautions, S28
Transplantation, haploidentical, 311
Trastuzumab, 319
clinical trials of, 48
Trovafloxacin, 319
Tumor necrosis factor-alpha inhibitors, 319
Tunneled centrally placed central venous catheters, vs. peripherally inserted catheters, in gastrointestinal cancer, 38

U

Ulcerative colitis, in adolescents, 255
Ultrasound, venous, in placement of peripherally inserted central venous catheters, 326
Urokinase, for catheter occlusion, S9, S13

V

Vascular access devices. *See* Central venous catheter(s)
Venous thrombosis, catheter-related, S9, S13. *See also* Catheter occlusion
Venous ultrasound, in placement of peripherally inserted central venous catheters, 326
Vitamins, for wound healing, 124

W

Wound healing, nutrient recommendations for, 124

Y

Y-90 yitrium ibritumomab, 319

Z

Zinc, for wound healing, 124